Evolving Treatment Concepts and New Data in Advanced Prostate Cancer is organized by i3 Health.

Dates Available:
02/10/2023 - 02/09/2024

Statement of Need:
Prostate cancer is the most common tumor type affecting men in the United States. It is estimated that 268,490 new cases were diagnosed and that 34,500 people died of prostate cancer in 2022 (Siegel et al, 2022). Prostate cancer alone accounts for 27% of all cancer diagnoses in men (ACS, 2022). To optimize outcomes for patients with prostate cancer, it is critical for health care providers to be familiar with the most recent evidence on therapy selection, biomarker testing, and the safety and efficacy of novel therapies for castration-sensitive prostate cancer (CSPC) and castration-resistant prostate cancer (CRPC). In this activity presented at the Society of Government Service Urologists James C. Kimbrough Urological Seminar, Tanya Dorff, MD, Section Chief of the Genitourinary Disease Program at City of Hope, provides expert guidance on evolving treatment paradigms in castration-sensitive and castration-resistant prostate cancer.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Distinguish biomarkers and clinical characteristics that can guide therapy selection for patients with prostate cancer
  • Assess practice guidelines on biomarker testing for patients with prostate cancer
  • Evaluate recent clinical trial findings on novel treatment strategies for metastatic castration-sensitive prostate cancer (CSPC)
  • Appraise emerging data on novel combination and sequential treatment strategies for nonmetastatic and metastatic castration-resistant prostate cancer (CRPC)


PhysicianNursingPhysician AssistantOncologistsUrologistsHealthcare Professionals




For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:

  • The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
  • The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.


Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
1 AMA PRA Category 1 Credit™ ...
More actions
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
1 AMA PRA Category 1 Credit™ ...
More actions
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
Jun 13, 2023 - Jun 12, 2024 | Webcast
Colon and Rectal Surgery
1 AMA PRA Category 1 Credit™ ...
More actions